| Reference-based Pricing: the Good, the Bad and the Ugly
In this presentation, Dr. Hornberger discussed value-based pricing, as it relates to molecular diagnostics and the future of personalized medicine. He also covered validation of assays and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer, which is being published by the Journal of the National Cancer Institute.
Presented at the 4th Annual Personalized Medicine Conference, September 12 – 13, 2012, Boston, MA
|A revised framework for appraising novel molecular classifiers
Presented at the 14th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 2009
| Gaining coverage and reimbursement in the age of comparative effectiveness
Presented at the June 2009 evening meeting of the Bio2Device Group